• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by CG Oncology Inc.

    9/18/25 8:37:24 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGON alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    CG Oncology, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    156944100

    (CUSIP Number)


    Patrick G. Enright
    Longitude Capital Partners IV, LLC, 2740 Sand Hill Road, 2nd Floor
    Menlo Park, CA, 94025
    (650) 854-5700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    09/11/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Longitude Capital Partners IV, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,190,463.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,190,463.00
    11Aggregate amount beneficially owned by each reporting person

    3,190,463.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    All such shares are held of record by LVPIV (as defined in Item 2(a) below). LCPIV (as defined in Item 2(a) below) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock (as defined in Item 2(d) below) outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer (as defined in Item 1(b) below) in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission (the "Commission") on August 8, 2025 (the "Form 10-Q"), plus (ii) 1,515,151 Shares purchased by Seven Fleet (as defined in Item 5(a) below) on September 11, 2025.


    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Longitude Venture Partners IV, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,190,463.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,190,463.00
    11Aggregate amount beneficially owned by each reporting person

    3,190,463.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    All such shares are held of record by LVPIV. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.


    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Longitude Prime Partners, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,471,805.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,471,805.00
    11Aggregate amount beneficially owned by each reporting person

    1,471,805.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    All such shares are held of record by LPF (as defined in Item 2(a) below). LPP (as defined in Item 2(a) below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.


    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Longitude Prime Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,471,805.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,471,805.00
    11Aggregate amount beneficially owned by each reporting person

    1,471,805.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.9 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    All such shares are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.


    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Patrick G. Enright
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,662,268.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,662,268.00
    11Aggregate amount beneficially owned by each reporting person

    4,662,268.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.0 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    All such shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Mr. Enright is a managing member of each of LCPIV and LPP and may be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.


    SCHEDULE 13D

    CUSIP No.
    156944100


    1 Name of reporting person

    Juliet Tammenoms Bakker
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,662,268.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,662,268.00
    11Aggregate amount beneficially owned by each reporting person

    4,662,268.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.0 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    All such shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Ms. Bakker is a managing member of each of LCPIV and LPP and may be deemed to share voting, investment and dispositive power with respect to these shares. Based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet on September 11, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    CG Oncology, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    400 Spectrum Center Drive, Suite 2040, Irvine, CALIFORNIA , 92618.
    Item 2.Identity and Background
    (a)
    This joint statement on Schedule 13D is being filed by Longitude Capital Partners IV, LLC ("LCPIV"), Longitude Venture Partners IV, L.P. ("LVPIV"), Longitude Prime Partners, LLC ("LPP") and Longitude Prime Fund, L.P. ("LPF", and together with LCPIV, LVPIV and LPP, the "Reporting Entities") and Patrick G. Enright and Juliet Tammenoms Bakker (together, the "Reporting Individuals"). The Reporting Entities and the Reporting Individuals are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The securities were previously reported on a Schedule 13G filed with the Commission on February 5, 2024 (the "Schedule 13G"). The Schedule 13G was filed pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Exchange Act is attached to this Schedule 13D as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Schedule 13D except to the extent of such Reporting Person's pecuniary interest therein.
    (b)
    The address of the principal business office of each Reporting Person is 2740 Sand Hill Road, 2nd Floor, Menlo Park, CA 94025.
    (c)
    Each Reporting Entity is a venture capital investment entity. Each Reporting Individual is engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes. The Reporting Individuals are managing members of LCPIV and LPP. LCPIV is the general partner of LVPIV. LPP is the general partner of LPF
    (d)
    During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    LCPIV and LPP are limited liability companies organized under the laws of the State of Delaware. LVPIV and LPF are limited partnerships organized under the laws of the State of Delaware. Each of the Reporting Individuals is a citizen of the United States of America.
    Item 3.Source and Amount of Funds or Other Consideration
     
    In September 2022, LVPIV purchased 21,547,685 shares of the Issuer's Series E redeemable convertible preferred stock for a purchase price of $1.0674 per share and an aggregate purchase price of $22,999,998.97. In May 2023, LVPIV entered into a common stock transfer agreement with various holders of the Issuer's capital stock pursuant to which LVPIV purchased 8,873,500 shares of common stock at a purchase price of $0.80055 per share for an aggregate purchase price of $7,103,680.43 (the "May 2023 Longitude Secondary Transaction"). In connection with the May 2023 Longitude Secondary Transaction, the Issuer entered into a common stock transfer agreement with LVPIV and each seller pursuant to which, among other things, the Issuer waived its right of first refusal to purchase the shares of common stock sold in the May 2023 Longitude Secondary Transaction. In July 2023, LPF purchased 4,402,320 shares of the Issuer's Series F redeemable convertible preferred stock for a purchase price of $1.2872 per share and an aggregate purchase price of approximately $5.6 million. In July 2023, LPF entered into a stock transfer agreement with Lepu Holdings Limited pursuant to which LPF purchased 3,512,646 shares of Series C redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of $3,187,023.72 (the "July 2023 Longitude Secondary Transaction"). Jue Pu, a former director of the Issuer, was an affiliate of Lepu Holdings Limited at the time of the July 2023 Longitude Secondary Transaction. In August 2023, LPF entered into a stock transfer agreement with an entity affiliated with a holder of the Issuer's capital stock pursuant to which LPF sold 1,756,323 shares of Series C redeemable convertible preferred stock at a sale price of $0.9073 per share for an aggregate sale price of $1,593,511.86 (the "August 2023 Longitude Secondary Transaction"). In connection with the August 2023 Longitude Secondary Transaction and the July 2023 Longitude Secondary Transaction, the Issuer entered into stock transfer agreements with LPF and each counterparty. In October 2023, Abundant Supply Global Limited, an entity affiliated with ORI Capital, a greater than 5% stockholder the Issuer, entered into stock transfer agreements with certain other holders of the Issuer's capital stock pursuant to which Abundant Supply Global Limited sold an aggregate of 27,190,800 shares of Series C redeemable convertible preferred stock at a purchase price of $1.2872 per share for an aggregate purchase price of $34,999,997.84. In connection with these transactions, LPF purchased 3,107,520 shares of Series C redeemable convertible preferred stock from Abundant Supply Global Limited for an aggregate purchase price of approximately $4 million. On January 29, 2024, effective upon the closing of the Issuer's initial public offering of its Common Stock (the "Offering"), each series of the Issuer's preferred stock automatically converted into shares of the Issuer's Common Stock on a one-for-9.535 basis for no consideration. All shares of the capital stock of the Issuer purchased by LVPIV and LPF have been purchased using investment funds provided to LVPIV and LPF by its limited partner and general partner investors. Unless noted above, no part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.
    Item 4.Purpose of Transaction
     
    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. In addition, Brian Liu, a managing director at LCM, serves on the board of directors of the Issuer. In such capacity, Mr. Liu, as well as other representatives of LCM or the Reporting Entities, expect to engage in communications from time to time with one or more shareholders, officers or members of the Issuer, including discussions regarding the Issuer's operations and strategic direction and ideas that, if effected, could result in, among other things, any of the matters identified in Item 4(a)-(j) of Schedule 13D. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve their right, based on all relevant factors and subject to applicable law, at any time or from time to time, to review or reconsider their position, change their purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in Items 4(a)-(j) of Schedule 13D) or formulate and implements plans or proposals with respect to any of the foregoing.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Items 7-11 of the cover pages of this Statement and Item 2(a) above. LVPIV is the record owner of 3,190,463 shares of Common Stock (the LVPIV Shares) and LPF is the record owner of 1,471,805 shares of Common Stock (the LPF Shares). As general partner of LVPIV, LCPIV may be deemed to beneficially own the LVPIV Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may be deemed to share voting, investment and dispositive power with respect to the LVPIV Shares. As general partner of LPF, LPP may be deemed to beneficially own the LPF Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power with respect to the LPF Shares. * Except to the extent of his, hers, or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. Longitude Capital Management Co. LLC ("LCM"), the investment advisor of LVPIV and LPF, and Seven Fleet Advisors LLC (together with its affiliates, "Seven Fleet") have instituted policies and procedures that may affect the acquisition, holding and disposition of securities held by Seven Fleet. As a result of such policies and procedures, the Reporting Persons and Seven Fleet may be deemed to be members of a group within the meaning of Section 13(d)(3) of the Exchange Act. As of the date hereof, based on information provided by or on behalf of Seven Fleet, Seven Fleet may be deemed to be the beneficial owner of 1,515,151 shares of Common Stock, constituting 1.9% of the number of shares of Common Stock outstanding (based on 77,762,732 shares of Common Stock outstanding, consisting of (i) 76,247,581 shares of Common Stock outstanding as of August 6, 2025, as reported by the Issuer in the Form 10-Q, plus (ii) 1,515,151 Shares purchased by Seven Fleet September 11, 2025). Notwithstanding such policies and procedures, the Reporting Persons expressly disclaim such group membership and beneficial ownership over any Common Stock that they may be deemed to beneficially own by reason of such policies and procedures. This Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 of the Exchange Act or for any other purpose.
    (b)
    See Items 7-11 of the cover pages of this Statement and Item 2(a) and Item 5(a) above.
    (c)
    Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.
    (d)
    Under certain circumstances set forth in the limited partnership agreements of LVPIV and LPF, the general partner and limited partners of LVPIV and LPF, respectively, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
    (e)
    Not applicable
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The Reporting Persons and certain of the Issuer's other investors entered into the Amended and Restated Investors' Rights Agreement, dated July 28, 2023 (the "Rights Agreement"). After the closing of the Offering, the stockholders party thereto are entitled to certain registration rights, including the right to demand that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1 (File No. 333-276350) and declared effective by the Commission on January 24, 2024 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1: Joint Filing Agreement, dated September 18, 2025, by and among the Reporting Persons (filed herewith). Exhibit 2: Amended and Restated Investors' Rights Agreement, dated July 28, 2023, by and among the Registrant and certain of its stockholders, (filed as Exhibit 4.2 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 23, 2024 (SEC File No. 333-276350) and incorporated herein by reference).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Longitude Capital Partners IV, LLC
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
    Date:09/18/2025
     
    Longitude Venture Partners IV, L.P.
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
    Date:09/18/2025
     
    Longitude Prime Partners, LLC
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
    Date:09/18/2025
     
    Longitude Prime Fund, L.P.
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
    Date:09/18/2025
     
    Patrick G. Enright
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira as attorney-in-fact for Patrick G. Enright
    Date:09/18/2025
     
    Juliet Tammenoms Bakker
     
    Signature:/s/ Cristiana Blauth Oliveira
    Name/Title:Cristiana Blauth Oliveira as attorney-in-fact for Juliet Tammenoms Bakker
    Date:09/18/2025
    Get the next $CGON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    8/19/2025$55.00Overweight
    Piper Sandler
    7/10/2025$40.00Buy
    Goldman
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    More analyst ratings

    $CGON
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by CG Oncology Inc.

    SCHEDULE 13D - CG Oncology, Inc. (0001991792) (Subject)

    9/18/25 8:37:24 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    9/18/25 4:28:51 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    9/15/25 4:30:32 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

    4/A - CG Oncology, Inc. (0001991792) (Issuer)

    4/9/24 7:08:23 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on CG Oncology with a new price target

    Piper Sandler initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00

    8/19/25 8:33:40 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on CG Oncology with a new price target

    Goldman resumed coverage of CG Oncology with a rating of Buy and set a new price target of $40.00

    7/10/25 8:53:17 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on CG Oncology with a new price target

    Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

    5/2/25 8:14:21 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulay James exercised 22,686 shares at a strike of $1.82 and sold $884,909 worth of shares (22,686 units at $39.01) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/22/25 7:30:03 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $35,100 worth of shares (1,000 units at $35.10) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/16/25 4:15:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/12/24 2:30:47 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/4/24 10:22:51 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CG Oncology Inc.

    SC 13G - CG Oncology, Inc. (0001991792) (Subject)

    7/22/24 4:35:57 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Financials

    Live finance-specific insights

    View All

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

    - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

    4/26/25 4:10:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

    IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

    4/24/25 8:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

    3/28/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

    - Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent - IRVINE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced updated data on BOND-003 Cohort C showing 12 additional patients with high risk non-muscle

    9/5/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Completes Enrollment in PIVOT-006

    – Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveil

    9/3/25 8:00:39 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care